Blogs
Healthcare and Medtech Research Reports
Sep 25, 2026
Summary On September 17, 2026, the FDA approved Ultragenyx’s FAYUVI (rebisufligene etisparvovec-hopf) as the first treatment targeting the underlying cause of Sanfilippo syndrome type A in pediatric patients with preserved neurodevelopmental function. Data from the pivotal Transpher A study and long-term fol...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper